

MarÃ-a DÃ-ez-Campelo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3098061/publications.pdf>

Version: 2024-02-01

26
papers

877
citations

840119

11
h-index

580395

25
g-index

28
all docs

28
docs citations

28
times ranked

1233
citing authors

#	ARTICLE	IF	CITATIONS
1	Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. <i>New England Journal of Medicine</i> , 2020, 382, 140-151.	13.9	335
2	Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents. <i>Journal of Clinical Oncology</i> , 2017, 35, 1591-1597.	0.8	79
3	Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML. <i>Leukemia</i> , 2021, 35, 2119-2124.	3.3	74
4	Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations. <i>British Journal of Haematology</i> , 2013, 162, 74-86.	1.2	73
5	Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy. <i>Blood</i> , 2019, 134, 2218-2222.	0.6	66
6	Single nucleotide polymorphism array karyotyping: A diagnostic and prognostic tool in myelodysplastic syndromes with unsuccessful conventional cytogenetic testing. <i>Genes Chromosomes and Cancer</i> , 2013, 52, 1167-1177.	1.5	44
7	Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML. <i>Blood Advances</i> , 2022, 6, 5132-5145.	2.5	43
8	Guiding the global evolution of cytogenetic testing for hematologic malignancies. <i>Blood</i> , 2022, 139, 2273-2284.	0.6	29
9	Use of newer prognostic indices for patients with myelodysplastic syndromes in the low and intermediate-1 risk categories: a population-based study. <i>Lancet Haematology</i> , 2015, 2, e260-e266.	2.2	24
10	Mesenchymal Stromal Cell Irradiation Interferes with the Adipogenic/Osteogenic Differentiation Balance and Improves Their Hematopoietic-Supporting Ability. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 443-451.	2.0	16
11	Deferasirox reduces oxidative DNA damage in bone marrow cells from myelodysplastic patients and improves their differentiation capacity. <i>British Journal of Haematology</i> , 2019, 187, 93-104.	1.2	12
12	Co-occurrence of cohesin complex and Ras signaling mutations during progression from myelodysplastic syndromes to secondary acute myeloid leukemia. <i>Haematologica</i> , 2021, 106, 2215-2223.	1.7	12
13	Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial. <i>Blood</i> , 2022, 139, 624-629.	0.6	12
14	Azacitidine improves outcome in higher-risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries. <i>British Journal of Haematology</i> , 2018, 181, 350-359.	1.2	11
15	Clinical and biological significance of isolated Y chromosome loss in myelodysplastic syndromes and chronic myelomonocytic leukemia. A report from the Spanish MDS Group. <i>Leukemia Research</i> , 2017, 63, 85-89.	0.4	9
16	Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations. <i>British Journal of Haematology</i> , 2021, 194, 708-717.	1.2	7
17	Hidden myelodysplastic syndrome (MDS): A prospective study to confirm or exclude MDS in patients with anemia of uncertain etiology. <i>International Journal of Laboratory Hematology</i> , 2019, 41, 109-117.	0.7	5
18	Analysis of Intratumoral Heterogeneity in Myelodysplastic Syndromes with Isolated del(5q) Using a Single Cell Approach. <i>Cancers</i> , 2021, 13, 841.	1.7	5

#	ARTICLE	IF	CITATIONS
19	Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. <i>Leukemia</i> , 2022, 36, 1432-1435.	3.3	5
20	Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis-stimulating agents. <i>Leukemia Research</i> , 2020, 99, 106472.	0.4	4
21	Distinct mutational pattern of myelodysplastic syndromes with and without 5q del treated with lenalidomide. <i>British Journal of Haematology</i> , 2020, 189, e133-e137.	1.2	4
22	Genome-wide transcriptomics leads to the identification of deregulated genes after deferasirox therapy in low-risk MDS patients. <i>Pharmacogenomics Journal</i> , 2020, 20, 664-671.	0.9	3
23	A myeloid neoplasm with <i>FIP1L1-PDGFRα</i> presenting as acute myeloid leukemia. <i>American Journal of Hematology</i> , 2020, 95, 1214-1215.	2.0	1
24	Multicenter Next-Generation Sequencing Studies between Theory and Practice. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 347-357.	1.2	1
25	The implication of "unknown significance" variants in next-generation sequencing in diagnosis and donor selection for allogeneic haematopoietic stem cell transplantation. Report of a case of myelodysplastic syndrome with a polymorphism in the tyrosine kinase 2 (<i>TYK2</i>) gene. <i>British Journal of Haematology</i> , 2020, 189, e182-e184.	1.2	0
26	Daratumumab in transfusion-dependent patients with low or intermediate-risk myelodysplastic syndromes. <i>American Journal of Hematology</i> , 2021, 96, E111-E114.	2.0	0